FARMACIA HOSPITALARIA最新文献

{"title":"Perfil de los ensayos clínicos con medicamentos para la infección por coronavirus del síndrome respiratorio agudo grave de tipo 2 (SARS-CoV-2) en España","authors":"Eduardo Tejedor-Tejada ,&nbsp;Cristina González-Pérez ,&nbsp;María del Puy Goyache Goñi ,&nbsp;María Pilar Suñé-Martín ,&nbsp;María Serrano-Alonso ,&nbsp;Rafael Sánchez-del Hoyo","doi":"10.1016/j.farma.2025.10.017","DOIUrl":"10.1016/j.farma.2025.10.017","url":null,"abstract":"<div><h3>Background</h3><div>On 11 March 2020, World Health Organisation declared COVID-19 a pandemic. During the early stages, treatments lacking scientific evidence, such as hydroxychloroquine and later remdesivir, were used; meanwhile, clinical trials were being conducted in Spain to evaluate new therapies with greater scientific rigor. This article analyses the study profile, publication rate and completion of studies during the COVID-19 pandemic in Spain.</div></div><div><h3>Methods</h3><div>Meta-epidemiological, analytical, and retrospective study analyzed the characteristics and rate of completion of clinical trials with SARS-CoV-2-related drugs authorized in Spain between March 2020 and March 2021, focusing on treatment and prophylaxis. 179 clinical trials were reviewed using sources such as Registro Español de Estudios Clínicos, <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span>, PubMed, Embase and TESEO. Statistical analysis was performed with SPSS v.26.</div></div><div><h3>Results</h3><div>67.0% of the trials were national and 71.0% multicentre, with non-commercial sponsors (64.8%) and phase II (44.7%) and phase III (48.0%) studies being the most common. The majority employed a comparative design (93.9%), preferentially focused on treatment (91.1%) versus prophylaxis of SARS-CoV-2 disease, with a predominance of therapeutic repositioning (72.1%). Notably, studies initiated during the first wave of the pandemic (March–June 2020) were mostly non-international, non-commercial, non-placebo-controlled and aimed at drug repositioning. Some 21.2% of the clinical trials closed prematurely, mainly due to recruitment problems, Involuntary discontinuation or Failure to achieve expected efficacy. By the end of the study, 41.1% of the clinical trials had a final report and 31.3% published their results, most of them (71.9%) in first quartile journals. Statistically significant associations were found between the publication of results and variables such as multicentre, not having closed prematurely, having a final report, and phase III trials.</div><div>The fact that a large number of clinical trials were not published (68.7%) represents a missed opportunity in terms of knowledge.</div></div><div><h3>Conclusion</h3><div>We conclude that there is a need to improve transparency, record all results– including negative ones– and review key aspects of design and funding, as recommendations for future research, including in health emergencies.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 144-150"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Desinfectantes de superficies utilizados en el ámbito sanitario","authors":"Isabel Romero Crespo ,&nbsp;Maria Luisa Gaspar Carreño ,&nbsp;Maria Cristina Muñoz Contreras","doi":"10.1016/j.farma.2025.03.011","DOIUrl":"10.1016/j.farma.2025.03.011","url":null,"abstract":"<div><h3>Objective</h3><div>Review the most relevant aspects to consider when selecting the optimal surface disinfectant for use in healthcare settings.</div></div><div><h3>Method</h3><div>The review was conducted over a three-month period (January to March 2024) based on the list of healthcare surface disinfectants authorized by the Spanish Agency of Medicines and Medical Devices and those in a transitional period, with marketing allowed until their registration in the Official Biocide Register. Biocidal agents belonging to the categories of skin antiseptics and insect repellents were excluded. A total of 100 biocidal agents were selected and evenly distributed among four researchers. The review strategy involved consulting the marketing representatives of these products via email or by reviewing their technical datasheets on their respective websites. The reviewed aspects of each disinfectant included marketed presentations, declared efficacy, composition, indication, dosage, and usage instructions.</div></div><div><h3>Results</h3><div>The total number of biocidal agents included in the study was 85. A total of 29 suppliers were consulted, covering 141 marketed presentations, 25 (29.41%) of which were sterile. Regarding the efficacy declared by suppliers, 100% (85 products) showed bactericidal activity, 81.18% (69) fungicidal activity, 78.82% (67) virucidal activity, 50.59% (43) yeasticidal activity, 20% (17) mycobactericidal/tuberculocidal activity, and 17.65% (15) sporicidal activity. In terms of usage instructions, 40 of the 85 biocides (47.06%) were presented in a ready-to-use dosage format, and 34 (40%) allowed for cleaning and disinfection in a single step. A total of 14 biocides (16.47%) included airborne disinfection options.</div></div><div><h3>Conclusions</h3><div>Selecting the most appropriate surface disinfectant is not straightforward, given the wide range of marketed products, the number of factors to consider, and the fact that not all products meet every criterion. For this reason, the selection process must be accompanied by the implementation of optimized programs aimed at reducing the transmission of pathogens from surfaces to patients and healthcare personnel</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 181-203"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145082085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alemtuzumab en esclerosis múltiple remitente-recurrente en práctica clínica: seguimiento anual de NEDA-3 hasta 4 años","authors":"Leticia Herrero-Poch ,&nbsp;Maria Susana Fortes-González ,&nbsp;Antonio Pato-Pato ,&nbsp;Pablo Gaveiras-Araújo ,&nbsp;Martín Lorenzo-García ,&nbsp;Daniel Apolinar García-Estévez ,&nbsp;Jose Ramón Lorenzo-González","doi":"10.1016/j.farma.2025.10.011","DOIUrl":"10.1016/j.farma.2025.10.011","url":null,"abstract":"<div><h3>Objective</h3><div>The effectiveness of alemtuzumab in patients with relapsing–remitting multiple sclerosis (RRMS) have been demonstrated in clinical trials. The primary endpoint was to describe the annual effectiveness of alemtuzumab over a 4-year period, according to the different parameters of the NEDA-3 concept (no evidence of disease activity) in clinical practice.</div></div><div><h3>Methods</h3><div>A retrospective, observational multicentric open study of patients with RRMS treated with alemtuzumab between 2015 and 2024. Effectiveness was assessed according to different parameters of the NEDA-3 concept (absence of relapses, stability in disability status according to the EDSS scale, and absence of new lesions and/or contrast enhancement in brain magnetic resonance imaging) with annual follow-up for up to four years.</div></div><div><h3>Results</h3><div>A cohort of 32 patients (71.9% women, mean age 40.3 ± 11 years) were included. The proportion of patients achieving NEDA-3 was 51.7% (15/29) in the first year, 56.2% (12/26) in the second year, 47.4% (9/19) in the third year, and 47.1% (8/17) in the fourth year. At the end of the study, 82% of patients remained relapse-free, 59% had stable disability according to the EDSS scale, and over 47% were free of radiological activity.</div></div><div><h3>Conclusions</h3><div>Alemtuzumab has proven to be effective, over 4 years, in clinical practice in patients with RRMS according to the different parameters of the NEDA-3 concept.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 158-161"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145641006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Abordaje multidisciplinar de la fibrosis quística prenatal con moduladores del regulador de la conductancia transmembrana de la fibrosis quística: experiencia en un caso clínico","authors":"Pedro del Palacio-García ,&nbsp;Carmen García-Muñoz ,&nbsp;María Dolores Canales-Siguero ,&nbsp;Maria Carmen Luna-Paredes ,&nbsp;Enrique Salcedo-Lobato ,&nbsp;Fernando Huecas-Jiménez ,&nbsp;Carlota Esperanza Vaquer-Ferrer ,&nbsp;José Miguel Ferrari-Piquero","doi":"10.1016/j.farma.2025.09.003","DOIUrl":"10.1016/j.farma.2025.09.003","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 204-207"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145410353","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Necrosis esofágica aguda en paciente con cáncer de pulmón bajo tratamiento con osimertinib: caso clínico","authors":"Alicia Aguado-Paredes,&nbsp;Laura Moñino-Dominguez,&nbsp;Maria del Carmen Damas-Fuentes","doi":"10.1016/j.farma.2025.07.004","DOIUrl":"10.1016/j.farma.2025.07.004","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 208-210"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145056003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acercar la investigación, derribar barreras: la nueva frontera de los ensayos clínicos","authors":"José Luis Revuelta-Herrero ,&nbsp;Fernando Bustelo-Paz ,&nbsp;Vicente Escudero-Vilaplana ,&nbsp;Ana Herranz-Alonso","doi":"10.1016/j.farma.2025.12.008","DOIUrl":"10.1016/j.farma.2025.12.008","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 141-143"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146195835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Protocolo de desensibilización a pomalidomida en paciente con hipersensibilidad cutánea: caso clínico","authors":"Gabriel Martínez-Orea ,&nbsp;Carlos Devesa-García ,&nbsp;Laura Puente-Romero ,&nbsp;Marta Vela-Martínez ,&nbsp;Mariella R. Lindo-Gutarra ,&nbsp;Pedro L. Fernández-García","doi":"10.1016/j.farma.2025.09.002","DOIUrl":"10.1016/j.farma.2025.09.002","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 211-213"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145551285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"N-acetilcisteína: 50 años del descubrimiento de un antídoto que ha cambiado el pronóstico de la intoxicación por paracetamol","authors":"Santiago Nogué-Xarau ,&nbsp;Lidia Martínez-Sánchez ,&nbsp;Milagros García-Peláez ,&nbsp;Edurne Fernández de Gamarra-Martínez ,&nbsp;Núria Pi-Sala ,&nbsp;Àngels Gispert-Ametller ,&nbsp;Emilio Salgado-García ,&nbsp;Raquel Aguilar-Salmerón","doi":"10.1016/j.farma.2025.07.005","DOIUrl":"10.1016/j.farma.2025.07.005","url":null,"abstract":"<div><div>Acetaminophen is one of the most widely used drugs in clinical practice due to its analgesic and antipyretic properties. However, overdose is one of the leading causes of severe acute liver failure. N-acetylcysteine, introduced as an antidote in 1974, has revolutionized the management of this intoxication by reducing hepatotoxicity and mortality associated with acetaminophen toxicity.</div><div>At the end of the 19th century, acetaminophen was identified as the main active metabolite of phenacetin and acetanilide. Its therapeutic use began to gain popularity in the 1950s and later became one of the main drugs involved in suicide attempts, particularly among adolescents and young adults. Acetaminophen-induced hepatotoxicity was first described in 1966, establishing that an overdose could lead to fulminant hepatic necrosis. In 1975, Rumack and Matthew published a nomogram that allowed stratification of hepatic toxicity risk based on plasma drug levels.</div><div>The mechanism of hepatotoxicity was elucidated in the early 1970s when it was discovered that acetaminophen is metabolized by cytochrome P450 into a highly reactive intermediate, N-acetyl-p-benzoquinoneimine, which is normally neutralized by hepatic glutathione. In overdose situations, glutathione depletion leads to hepatic necrosis. Based on these findings, sulfhydryl-containing agents such as cysteamine and methionine were introduced as antidotes, but N-acetylcysteine ultimately proved to be the most effective treatment.</div><div>Since its introduction, N-acetylcysteine administration protocols have evolved to optimize efficacy and minimize adverse effects. Protocols such as the Scottish and Newcastle Acetylcysteine Protocol and the Two Bags regimen have simplified dosing and reduced the incidence of anaphylactoid reactions.</div><div>Over the past 50 years, N-acetylcysteine has saved thousands of lives and remains the gold-standard antidotal treatment for acetaminophen poisoning.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages 162-166"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144973730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] N-acetylcysteine: 50 years since the discovery of an antidote that has changed the prognosis of acetaminophen poisoning","authors":"Santiago Nogué-Xarau ,&nbsp;Lidia Martínez-Sánchez ,&nbsp;Milagros García-Peláez ,&nbsp;Edurne Fernández de Gamarra-Martínez ,&nbsp;Núria Pi-Sala ,&nbsp;Àngels Gispert-Ametller ,&nbsp;Emilio Salgado-García ,&nbsp;Raquel Aguilar-Salmerón","doi":"10.1016/j.farma.2025.10.015","DOIUrl":"10.1016/j.farma.2025.10.015","url":null,"abstract":"<div><div>Acetaminophen is one of the most widely used drugs in clinical practice due to its analgesic and antipyretic properties. However, overdose is one of the leading causes of severe acute liver failure. N-acetylcysteine, introduced as an antidote in 1974, has revolutionized the management of this intoxication by reducing hepatotoxicity and mortality associated with acetaminophen toxicity.</div><div>At the end of the 19th century, acetaminophen was identified as the main active metabolite of phenacetin and acetanilide. Its therapeutic use began to gain popularity in the 1950s and later became one of the main drugs involved in suicide attempts, particularly among adolescents and young adults. Acetaminophen-induced hepatotoxicity was first described in 1966, establishing that an overdose could lead to fulminant hepatic necrosis. In 1975, Rumack and Matthew published a nomogram that allowed stratification of hepatic toxicity risk based on plasma drug levels.</div><div>The mechanism of hepatotoxicity was elucidated in the early 1970s when it was discovered that acetaminophen is metabolized by cytochrome P450 into a highly reactive intermediate, N-acetyl-p-benzoquinoneimine, which is normally neutralized by hepatic glutathione. In overdose situations, glutathione depletion leads to hepatic necrosis. Based on these findings, sulfhydryl-containing agents such as cysteamine and methionine were introduced as antidotes, but N-acetylcysteine ultimately proved to be the most effective treatment.</div><div>Since its introduction, N-acetylcysteine administration protocols have evolved to optimize efficacy and minimize adverse effects. Protocols such as the Scottish and Newcastle Acetylcysteine Protocol and the Two Bags regimen have simplified dosing and reduced the incidence of anaphylactoid reactions.</div><div>Over the past 50 years, N-acetylcysteine has saved thousands of lives and remains the gold-standard antidotal treatment for acetaminophen poisoning.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T162-T166"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145640998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Translated article] Making research accessible, breaking down barriers: the new frontier of clinical trials","authors":"José Luis Revuelta-Herrero ,&nbsp;Fernando Bustelo-Paz ,&nbsp;Vicente Escudero-Vilaplana ,&nbsp;Ana Herranz-Alonso","doi":"10.1016/j.farma.2026.02.001","DOIUrl":"10.1016/j.farma.2026.02.001","url":null,"abstract":"","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"50 3","pages":"Pages T141-T143"},"PeriodicalIF":1.3,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147311204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}